ClinicalTrials.gg
CompletedNCT04466618Updated Dec 26, 2023Results posted

Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

A Phase 3 interventional study of Saline and Exendin-9,39 in Healthy and Type 2 Diabetes, sponsored by Adrian Vella. Completed at 1 site in United States. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-26.

Sponsored by Adrian Vella · Phase 3, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
2,441st of 2,961
23 · median 90
Started
2021
with 171 others
Phase 3
580 of 3,308
34 open now
Registered
2,368th of 3,308
by date

Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,441st largest by enrollment of the 2,961 interventional ones that give a count, is one of 172 that started in 2021, is one of 580 in phase 3, and was the 2,368th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

340 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

GLP-1 is a hormone made by the body that promotes the production of insulin in response to GLP-1 is produced within the islets expressing prohormone convertase 1/3eating. However, there is increasing evidence that this hormone might help support the body's ability to produce insulin when diabetes develops. The purpose of this study is to determine the effect of endogenous GLP-1 secretion on insulin secretion in people with and without type 2 diabetes.

Read the detailed description

Accumulating evidence suggests that in rodents and humans GLP-1 is synthesized within islets and may act locally in a paracrine fashion. Indeed, mice with genetic loss of intra-islet GLP-1 exhibit decreased insulin secretion and impaired response to metabolic stressors. 'Pancreatic' GLP-1 may contribute to the effects of DPP-4 inhibitors in rodents and humans. Antagonism of GLP1R with exendin-9,39 during fasting impairs the islet cell response to an I.V. glucose challenge. Islet GLP-1 content is increased in T2DM and in islets from non-diabetic humans exposed to hyperglycemia and Free Fatty Acids. These observations imply that paracrine GLP-1 secretion supports islet function in the presence of glucolipotoxicity. In this experiment we will examine the role of endogenous GLP-1 secretion in people with and without T2DM and during β-cell stress induced by FFA elevation.

03

Conditions studied

  • Healthy
  • Type 2 Diabetes
04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria - non-diabetic subjects:

  • Weight-stable, non-diabetic subjects

Exclusion Criteria - non-diabetic subjects:

  • Age \< 25 or > 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).
  • ≥ 6.5%
  • Use of glucose-lowering agents.
  • For female subjects: positive pregnancy test at the time of enrollment or study
  • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • Active systemic illness or .
  • Symptomatic macrovascular or microvascular disease.

Inclusion criteria - diabetic subjects:

  • Weight-stable, diabetic subjects treated with diet and lifestyle alone or with metformin monotherapy

Exclusion Criteria - diabetic subjects:

  • Age \< 25 or > 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose).
  • Use of any glucose-lowering agent other than metformin.
  • 2 or more fasting glucose values > 250mg/dl on medication or after medication withdrawal.
  • Unwillingness or inability to withdraw medication for three weeks prior to, and for the duration of the study.
  • For female subjects: positive pregnancy test at the time of enrollment or study
  • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • Active systemic illness or malignancy.
  • Symptomatic macrovascular or microvascular disease.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Placebo comparator
    Saline

    Saline infusion

    Biological: Saline

  • Active comparator
    Exendin-9,39

    Exendin-9,39 infusion

    Biological: Exendin-9,39

  • Active comparator
    Saline + Intralipid/Heparin

    Induction of acute insulin resistance during Saline infusion

    Biological: Saline + Intralipid/Heparin

  • Active comparator
    Exendin-9,39 + Intralipid/Heparin

    Induction of acute insulin resistance during Exendin-9,39 infusion

    Biological: Exendin-9,39 + Intralipid/Heparin

Interventions

  • BiologicalSaline

    Saline infused during the study

  • BiologicalAvexitideStudies of AvexitideAvexitide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Exendin-9,39 infused during the study

  • BiologicalSaline + Intralipid/Heparin

    Saline infused during acute insulin resistance

  • BiologicalExendin-9,39 + Intralipid/Heparin

    Exendin-9,39 infused during acute insulin resistance

06

What researchers measure

Primary outcomes

  1. Change in Fasting Glucagon in the Presence or Absence of Exendin-9,39

    Concentrations of glucagon Measured by immunoassay over the -30 to 0 minutes of study. On one study day subjects received saline, on the other exendin-9,39. The infusion commenced at -120 minutes.

    Time frame: Average concentration over the -30 to 0 minutes of study

07

Results

Posted Dec 26, 2023

Participant flow

Participant flow — Overall Study
MilestoneNon-diabetic SubjectsSubjects With Type 2 Diabetes
Started1211
Completed1210
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryChange in Fasting Glucagon in the Presence or Absence of Exendin-9,39

Concentrations of glucagon Measured by immunoassay over the -30 to 0 minutes of study. On one study day subjects received saline, on the other exendin-9,39. The infusion commenced at -120 minutes.

Time frame:
Average concentration over the -30 to 0 minutes of study
Reported as:
Mean · pmol/l
Change in Fasting Glucagon in the Presence or Absence of Exendin-9,39
pmol/lNo DiabetesType 2 Diabetes
Saline7.4 ± 1.27.9 ± 0.3
Exendin 9-397.8 ± 1.110.2 ± 0.3

Adverse events

Collected over The 3 months of participation. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Non-diabetic Subjects Saline0/12 (0%)0/12 (0%)0/12 (0%)
Non-diabetic Subjects Exendin-9,390/12 (0%)0/12 (0%)0/12 (0%)
Non-diabetic Subjects Saline + Intralipid/Heparin0/12 (0%)0/12 (0%)0/12 (0%)
Non-diabetic Subjects Exendin-9,39 + Intralipid/Heparin:0/12 (0%)0/12 (0%)0/12 (0%)
Type 2 Diabetes Saline0/11 (0%)0/11 (0%)1/11 (9.1%)
Type 2 Diabetes Exendin-9,390/11 (0%)0/11 (0%)1/11 (9.1%)
Most frequent other events
Most frequent other events
EventNon-diabetic Subjects SalineNon-diabetic Subjects Exendin-9,39Non-diabetic Subjects Saline + Intralipid/HeparinNon-diabetic Subjects Exendin-9,39 + Intralipid/Heparin:Type 2 Diabetes SalineType 2 Diabetes Exendin-9,39
HyperglycemiaEndocrine disorders0/120/120/120/121/110/11
IV access lossVascular disorders0/120/120/120/120/111/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)No DiabetesType 2 DiabetesTotal
Mean54 ± 858 ± 556 ± 7
Sex: Female, Male
Sex: Female, Male(Participants)No DiabetesType 2 DiabetesTotal
Female8816
Male437
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)No DiabetesType 2 DiabetesTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)No DiabetesType 2 DiabetesTotal
United States121123
08

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Dec 2022, 20 months.

Results were first posted in Dec 2023, 1 year after primary completion.

Of 87 non-industry phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 20 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2020
First posted
Jul 10, 2020
StartActual
Apr 15, 2021
Primary completionActual
Dec 15, 2022
CompletionActual
Dec 31, 2022
Results first posted
Dec 26, 2023
Last update
Dec 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04466618
Lead sponsor
Adrian Vella
Responsible party
Adrian Vella (Principal Investigator, Mayo Clinic) — Sponsor-investigator
First posted
Jul 10, 2020
Start date
Apr 15, 2021
Primary completion
Dec 15, 2022
Completion
Dec 31, 2022
Results posted
Dec 26, 2023
Last update
Dec 26, 2023

Study contacts

Adrian Vella
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avexitide

Start the discussion